NEWCASTLE UPON TYNE, England, October 1, 2012 \/PRNewswire\/ -- <\/p>\n
Leica Biosystems announces the availability of the Novocastra HD menu for breast pathology, the first portfolio of independently qualified* antibodies from the new Novocastra HD range. Together with the FDA approval of the Leica BOND Oracle HER2 IHC System on April 18, 2012, this new menu affirms Leica Biosystems' position as a premier supplier of the most clinically important IHC systems and reagents for the diagnosis of breast cancer. <\/p>\n
(Photo: http:\/\/photos.prnewswire.com\/prnh\/20121001\/564961<\/a> )<\/p>\n The Novocastra HD menu for breast pathology comprises 37 products, developed following extensive research with pathologists and laboratory staff from around the globe. Novocastra HD products have been independently evaluated* by NordiQC in comparison with leading equivalents. Staining performance in Ready-to-Use format has been optimized on BOND instrumentation, delivering the crucial diagnostic confidence that underpins every patient diagnosis. Pathologists and laboratories can confidently select any Novocastra HD product, knowing that it has been externally benchmarked against leading equivalents for staining quality and diagnostic performance. <\/p>\n 'Leica Biosystems strives to achieve the utmost customer satisfaction and improvement in patient care through the pursuit of excellence in quality', says Arnd Kaldowski, President of Leica Biosystems. 'The new Novocastra HD menu for breast pathology was developed to meet our customers' need for clinically relevant antibodies that deliver high quality staining and results patients can depend on.' <\/p>\n The Novocastra HD breast pathology menu of IHC antibodies comprises twelve[#] clones in a range of formats and volumes. Many BOND Ready-to-Use antibodies come in two sizes: 7 mL and a new 30 mL size for higher usage requirements. Liquid concentrates are available in an expanded range of sizes from 0.1 mL to 2 mL. <\/p>\n The Novocastra HD menu for breast pathology will be available for sale in the USA and EU from September 2012. Availablility in other regions will follow. <\/p>\n Leica Biosystems offers histopathology laboratories the most extensive product range with appropriate products for each work step in histology and for a high level of productivity in the working processes of the entire laboratory. <\/p>\n The company is represented in over 100 countries with 12 manufacturing facilities in 7 countries, sales and service organizations in 19 countries and an international network of dealers. The company is headquartered in Wetzlar, Germany. <\/p>\n http:\/\/www.LeicaBiosystems.com<\/a> <\/p>\n<\/p>\n Continue reading here: NEWCASTLE UPON TYNE, England, October 1, 2012 \/PRNewswire\/ -- Leica Biosystems announces the availability of the Novocastra HD menu for breast pathology, the first portfolio of independently qualified* antibodies from the new Novocastra HD range. Together with the FDA approval of the Leica BOND Oracle HER2 IHC System on April 18, 2012, this new menu affirms Leica Biosystems' position as a premier supplier of the most clinically important IHC systems and reagents for the diagnosis of breast cancer. Continue reading
\nChoose Highly Definitive Antibodies for IHC with the new Leica Biosystems Novocastra HD Menu for Breast Pathology<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"